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Abstract 
Catheter ablation has, over the recent 
years, become central to the management of 
atrial fibrillation.  As the latest studies 
consistently demonstrate it safety and 
increasing efficacy, AF ablation is being 
performed in many centres worldwide, with 
a Class IA recommendation in those with 
recurrent symptomatic AF despite medical 
therapy. Concomitantly, continuous 
technological advances accompany the 
development on new electrophysiological 
techniques. 
In this review, the authors seek to 
address the need among the local medical 
community of more in-depth knowledge of 
the technique and its indications, especially 
in view of the recent introduction of such 
service at our national hospital. 
 
 
 
 
 
 
 
Introduction 
Atrial fibrillation (AF) is the most 
common sustained cardiac arrhythmia 
effecting two percent of the general 
population and one-in-ten octogenarians.1 
Around 8 million people are estimated to be 
effected in the EU, with the number 
predicted to double within the next half a 
century.1 Whilst up to 40% of patients are 
asymptomatic, others may experience 
disabling symptoms, primarily palpitations.2 
Antiarrhythmic drugs provide effective 
symptom control in a further 30%, with the 
other half of symptomatic AF patients 
failing drug therapy.2  
AF results from ectopic activity within 
the atria with subsequent complex multiple 
wavelet re-entry pathways.3 Permanent AF 
is the most common type, present in up to 
one half of effected patients, with the rest 
suffering from paroxysmal or persistent 
AF.1 This arrhythmia is associated with a 
negative impact on the quality of patient’s 
lives, a five-fold increase in the risk of 
stroke, higher incidence of heart failure as 
well as elevated health care costs from 
hospitalisations, interventions and 
medications.2 
Over the last two decades, AF ablation 
has evolved from a novel experimental 
procedure to a successful intervention 
performed at most large medical centres that 
provide a clinical cardiac electrophysiology 
service.   
Local experience 
Ablation for atrial fibrillation was 
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introduced locally in 2016 at Mater Dei 
Hospital. To date, 20 patients have 
undergone this intervention, with the 
majority being de novo cases. The technique 
used locally involves point by point 
radiofrequency ablation.  
 
Management 
Thromboprophylaxis is essential in the 
management of AF patients. Oral 
anticoagulation (OAC) can prevent 
ischaemic CVAs and reduce mortality in all 
patients except those at very low risk. 4  
The gold standard for risk stratification 
for thromboembolic events remains the 
CHA2DS2-VASc score, since its 
introduction in the 2010 ESC guidelines. 
The recently published 2016 guidelines have 
reduced to a Class IIa (level B) the 
indication for OACs in patients with one 
clinical risk factor (i.e. a CHA2DS2-VASc 
score of 1 for men, and 2 for women), and 
therefore treatment ‘should be considered’. 
This decision was based on the fact that 
whilst there is increasing evidence regarding 
stroke risk in these individuals, this is based 
mainly on observed stroke rates in patients 
not receiving OAC.  In CHA2DS2-VASc 
risk score of at least 2 in males, and 3 or 
more in females, evidence very strongly 
favours prophylaxic, with OAC maintaining 
a Class I (level A) recommendation.4  
The role of biomarkers such as high-
sensitivity troponin and NT pro-BNP as 
risk- stratifier is still being studied.5 Various 
bleeding scores have also been developed, 
namely HAS-BLED, ORBIT and ABC. 
These tools should be used to identify and 
correct modifiable risks elements, but in 
general should not lead to withholding 
OAC. Unfortunately, OAC is too commonly 
withheld for reasons including bleeding risk, 
patient frailty and complexity of VKA 
monitoring, even though mortality and 
morbidity rates from stroke still exceed 
those from bleeding in the majority of such 
patients.4 
Vitamin K antagonists (VKA) reduce 
risk of stroke by two-thirds and mortality by 
twenty-five percent.6 Its narrow therapeutic 
range and the need of frequent monitoring 
and dose modifications may, however, prove 
challenging. Novel oral anticoagulants 
(NOACs) are a non-inferior alternative that 
eliminate such drawbacks.7-8 In whom OAC 
is contra-indicated, left atrial appendage 
closure should be considered in order to 
reduce the risk of embolic strokes4. Aspirin 
with/out clopidogrel carries the same risk of 
bleeding as OAC without preventing strokes 
as effectively, and therefore antiplatelet 
therapy is not recommended.9  
The primary aim of AF therapy remains 
that of achieving and maintaining sinus 
rhythm, in order to relief symptoms, 
improve exercise tolerance, reduce 
thromboembolic risk and prevent 
cardiomyopathy. Sotalol or flecainide are 
first line in healthy individuals, whilst 
amiodarone is the treatment of chose in 
patient with heart failure. In the presence of 
coronary artery disease, sotolol should be 
used.  
Rate versus rhythm control has been 
studied in two major randomized trials, 
AFFIRM and RACE. There was no 
statistically significant difference in 
mortality between the two strategies, whilst 
the number of hospitalisations and adverse 
drug effects were lower in the rate control 
group. Both trials enrolled high risk patients 
with structural heart disease, and results 
therefore should not be extrapolated to 
healthy young individuals.10 
Rate control strategy is an acceptable 
alternative whereby the ventricular response 
rate of AF. This can be achieved by the use 
of medications that act on the atrio-
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ventricular (AV) node, supressing electrical 
conduction. If medical treatment fails, a last-
resort approach involves the insertion of a 
pacemaker (VVI) followed by ablation of 
the AV node. Such technique is relatively 
simple to implement, with both 
complication and mortality rate being low.11 
Patients, however, are rendered pacemaker 
dependent for the rest of their lives. Other 
comorbidities, such as the presence on heart 
failure, help determine the type of 
pacemaker used (uni- or bi- ventricular,12 
with/out ICD13). 
Maintenance of sinus rhythm is the 
main goal of the rhythm control strategy. 
Whilst antiarrhythmic drugs are first line in 
the rhythm control strategy of AF, catheter 
ablation can effectively restore sinus rhythm 
in those with recurrent symptomatic AF 
despite medical therapy (Class IA 
recommendation).4   In obese patients, since 
weight loss should be considered to reduce 
AF burden and symptoms (Class IIa 
recommendation),4 radiofrequency ablation 
should be offered in conjunction with 
lifestyle changes that promote weight 
reduction. 
Contraindications to the procedure 
include left atrial thrombus, contraindication 
to anticoagulation (required post-ablation), 
severe mitral valve disease or mechanical 
mitral valve prosthesis, severe pulmonary 
hypertension and pregnancy.4 
Patients considered to be potential 
candidates for AF ablation should be 
referred for review by an electrophysiologist 
in an outpatient’s setting and undergo 
various investigations a 12-lead ECG, 24-
hour Holter, echocardiography and cardiac 
CT/ MRI. Clinical evaluation and a 
discussion with the patient including 
benefits, risks and alternative strategies are 
crucial.  
Patients should be started on oral 
anticoagulants at last four weeks prior to this 
elective procedure, whilst antiarrhythmic 
drugs should be stopped to unmask 
abnormal electrical activity. Closer to the 
procedure, adequate hydration minimises the 
risk of contrast-induced nephropathy, 
management of medical co-morbidities 
should be optimised and consultation with 
an anaesthesiologist arranged to evaluate the 
airway and risks for general anaesthesia.  
Peri-procedurally, access to the left 
atrium is obtained transfemorally via a 
trans-septal approach. An oesophageal probe 
allows temperature monitoring to minimise 
risk of oesophageal damage and electrodes 
placed on the chest wall provide the 
electrical field used to create an anatomic 
map of the left atrium. Intravenous heparin 
is administered at the start of the procedure 
and activated clotting time (ACT) analysed 
every thirty minutes, giving further boluses 
of heparin as required in order to maintain 
ACT above 300ms 
Ectopic electrical activity in the 
pulmonary veins (PVs) has for long been 
considered the culprit in AF initiation. The 
aim of the primary intervention, therefore, is 
to segregate such substrate from the left 
atrium.14 The primary technique in AF 
ablation involves isolation of the pulmonary 
veins (Class IIa recommendation) through 
the creation of sequential point-by-point 
radiofrequency lesions over a 
circumferential margin encompassing all 
four PVs.15 Other regions may be ablated at 
repeat procedures, namely the atrial roof, 
cavotricuspid and mitral isthmi. 
Computerised electro-anatomic 
mapping systems allow the operator to 
create a three-dimensional image of the left 
atrium and the PVs that may also be merged 
with computerised-tomography or magnetic-
resonance scans acquired prior to the 
procedure. This enables real-time 
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identification of electrical and anatomic 
targets. Intracardiac pacing and sensing 
provides electrophysiological data with the 
purpose of localising abnormal electrical 
activity and assessing the effectiveness of 
the ablation at isolating it. 
An alternative technique to 
radiofrequency is cyroablation, that uses 
refrigerant N2O to induce tissues necrosis. 
Both methods have their advantages and 
drawbacks, with cryoablation considered to 
be performed with more ease whilst RF 
ablation allows more manoeuvrability as 
well as applicability to re-do procedures. 
FIRE and ICE, a multicenter, randomized 
trial by Kuck et al., showed non-inferiority 
of cryoablation versus RF ablation in both 
primary efficacy and safety end-points. 
Procedure time was longer, but fluoroscopy 
time shorter in the radiofrequency group.16 
What was their respective success rates? 
Which technique will win the race rests on 
further technological developments and the 
reproducibility of the results.  
Major complication rates have fallen 
below five percent in recent years. Cardiac 
tamponade, pericardial effusions, atrio-
oesophageal fistula, stroke, transient 
ischaemic attack, persistent phrenic nerve 
palsy, pulmonary vein stenosis and death 
have been reported. Other minor 
complications include femoral 
pseudoaneurysms and artero-venous 
fistulae. In an analyses by Yong-Soo Baek 
et al.17, persistent AF and duration of 
procedure were associated with higher rates 
of major complications.   
Close follow-up of patients after 
ablation is important especially in the initial 
phase where both patients and physicians 
should be aware of the signs and symptoms 
of complications, enabling prompt referral 
for their management. AF recurrences are 
not uncommon, with further rhythm control 
therapy being reserved mainly for the 
symptomatic patients. All post-ablation 
patients should be reviewed at last once by 
an electrophysiologist during the first year 
post-procedure. 
Observational studies indicate that the 
risk of thromboembolic event is low after 
AF ablation, yet data and risk stratification 
has been adopted from non-ablation AF 
cohorts. Patients should remain 
anticoagulated for at last two months after 
ablation. The decision for long term use of 
anticoagulants post-procedure should be 
based on general anticoagulation 
recommendations, the long-term risk of 
recurrent AF and the safety profile of 
anticoagulation.  
 
Way forward 
Ongoing advances in technique and 
technology are reflected in more durable PV 
isolation and lower rates of AF recurrence 
post-ablation. Ouyang F et al. [Circulation, 
2010] reported only 6% of patients with 
complete PVI at repeat procedure using 1st 
generation radiofrequency catheters.  Recent 
figures indicate up to 66% durability of PV 
isolation with 2nd generation RF 
technology.18 The use of real-time contact 
force measurements has increased atrial 
arrhythmia freedom in comparison to a 
standard non-force sensing catheter (88% 
versus 66% of patients respectively), though 
this came at the expense of longer procedure 
and fluoroscopy time.19 Ablation technique 
developments, such as the ‘CLOSE’ 
protocol, have also paved the way for better 
success rates as measured by post single-
procedure freedom from atrial fibrillation or 
tachycardia.20 The future is even more 
promising with 3rd generation devices 
providing more reliable temperature and 
EGM at the tip-tissue interface as well as 
temperature controlled irrigated RF ablation 
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with high-resolution EGM. In addition, the 
advent of catheters using ultrasound and 
laser modalities may also contribute towards 
further improvements. Concurrently, better 
mapping technologies are being developed.  
With ever increasing success rates, ablation 
may in the near future become the first line 
treatment of choice. Data from the RAFT-2 
study has demonstrated a lower rate of 
recurrence at two-year follow-up in patients 
undergoing RF ablation versus 
antiarrhythmic drugs.21  
Conclusion 
Atrial fibrillation is an increasingly 
common condition with a high burden on 
our health system. Further developments in 
techniques and technologies, together with 
data from recent studies, are reflected in the 
recently published 2016 ESC Guidelines for 
the management of atrial fibrillation. The 
principles of management, however, remain 
those of appropriate anticoagulation coupled 
with a rate or rhythm control strategy, with 
the aim of controlling symptoms and 
reducing morbidity and mortality.  
To date, the mainstay of the rhythm 
control strategy is pulmonary vein isolation 
either by RF ablation or cryoablation. 
Alternatively, rate control has been shown to 
be a non-inferior option for the management 
of AF patients. The CHA2DS2-VASc score 
keeps its place as the gold-standard risk-
stratification tool for thromboprophylaxic.   
Whilst most patient can be managed by their 
physicians, those with symptomatic AF 
should be referred for assessment by an 
electrophysiologist, especially if symptoms 
persist despite medical therapy.  
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